Bosh sahifaMEHCQ • OTCMKTS
add
23andMe Holding Co.
Yopilish kursi
1,17 $
Kunlik diapazon
1,07 $ - 1,18 $
Yillik diapazon
0,48 $ - 12,76 $
Bozor kapitalizatsiyasi
30,85 mln USD
Oʻrtacha hajm
8,09 mln
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
OTCMKTS
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(USD) | dek, 2024info | Y/Y qiyosi |
---|---|---|
Daromad | 60,26 mln | 34,67% |
Joriy xarajat | 65,06 mln | -22,18% |
Sof foyda | -53,04 mln | 80,92% |
Sof foyda marjasi | -88,01 | 85,83% |
Har bir ulushga tushum | — | — |
EBITDA | -21,80 mln | 62,70% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
(USD) | dek, 2024info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 79,35 mln | -67,27% |
Jami aktivlari | 277,42 mln | -54,39% |
Jami passivlari | 214,70 mln | -7,06% |
Umumiy kapital | 62,72 mln | — |
Tarqatilgan aksiyalar | 26,83 mln | — |
Narxi/balansdagi bahosi | 0,50 | — |
Aktivlardan daromad | -21,15% | — |
Kapitaldan daromad | -42,49% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(USD) | dek, 2024info | Y/Y qiyosi |
---|---|---|
Sof foyda | -53,04 mln | 80,92% |
Operatsiyalardan naqd pul | -44,65 mln | -270,23% |
Sarmoyadan naqd pul | 887,00 ming | 144,09% |
Moliyadan naqd pul | -19,00 ming | -118,10% |
Naqd pulning sof oʻzgarishi | -43,79 mln | -213,47% |
Boʻsh pul | -20,18 mln | -469,10% |
Haqida
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California. It is best known for providing a direct-to-consumer genetic testing service in which customers provide a saliva sample that is laboratory analysed, using single nucleotide polymorphism genotyping, to generate reports relating to the customer's ancestry and genetic predispositions to health-related topics. The company's name is derived from the 23 pairs of chromosomes in a diploid human cell.
Founded in 2006, 23andMe soon became the first company to begin offering autosomal DNA testing for ancestry, which all other major companies now use. Its saliva-based direct-to-consumer genetic testing business was named "Invention of the Year" by Time in 2008.
The company had a previously fraught relationship with the United States Food and Drug Administration due to its genetic health tests; as of October 2015, DNA tests ordered in the US include a revised health component, per FDA approval. 23andMe has been selling a product with both ancestry and health-related components in Canada since October 2014, and in the UK since December 2014. Wikipedia
Tashkil etilgan
apr 2006
Sayt
Xodimlar soni
571